
COMMISSION IMPLEMENTING DECISION of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 516) (Text with EEA relevance) (2012/68/EU) 

THE EUROPEAN COMMISSION,
Having regard to the Treaty on European Union and the Treaty on the Functioning of the European Union,
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, and in particular Article 16f thereof,
Having regard to the opinion of the European Medicines Agency, formulated on 15 July 2010 by the Committee for Herbal Medicinal Products,
Whereas:

(1) Vitis vinifera L. can be considered as a herbal substance, a herbal preparation or a combination thereof within the meaning of Directive 2001/83/EC and it complies with the requirements set out in that Directive.

(2) It is therefore appropriate to include Vitis vinifera L. in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established by Commission Decision 2008/911/EC.

(3) Decision 2008/911/EC should therefore be amended accordingly.

(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,
HAS ADOPTED THIS DECISION:

Article 1 
Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.
Article 2 
This Decision is addressed to the Member States.
Done at Brussels, 3 February 2012.
For the Commission
John DALLI
Member of the Commission
ANNEX

Decision 2008/911/EC is amended as follows:

((1)) in Annex I, the following substance is inserted after Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum:
'Vitis vinifera L., folium'
((2)) in Annex II, the following is inserted after the entry on Thymus vulgaris L., Thymus zygis Loefl. ex L.:
'COMMUNITY LIST ENTRY ON VITIS VINIFERA L., FOLIUM 
Scientific name of the plant 

Vitis vinifera L.
Botanical family 

Vitaceae
Herbal substance 

Grapevine leaf
Common name of herbal substance in all EU official languages 


 BG (bălgarski): лоза, лист
 CS (čeština): Červený list vinné révy
 DA (dansk): Vinblad
 DE (Deutsch): Rote Weinrebenblätter
 EL (elliniká): Φύλλο Αμπέλου
 EN (English): Grapevine leaf
 ES (español): Vid, hoja de
 ET (eesti keel): Viinapuu lehed
 FI (suomi): Aitoviiniköynnös, lehti
 FR (français): Feuille de vigne rouge
 HU (magyar): Bortermő szőlő levél
 IT (italiano): Vite, foglia
 LT (lietuvių kalba): Tikrųjų vynmedžių lapai
 LV (latviešu valoda): Īstā vīnkoka lapas
 MT (malti): Werqa tad-dielja
 NL (nederlands): Wijnstokblad
 PL (polski): Liść winorośli właściwej
 PT (português): Folha de videira
 RO (română): Frunze de viță-de-vie
 SK (slovenčina): List viniča
 SL (slovenščina): List vinske trte
 SV (svenska): Blad från vinranka
 IS (íslenska): Vínviðarlauf
 NO (norsk): Rød vinranke, blad
Herbal preparation(s) 

Soft extract (2.5-4:1; extraction solvent water)
European Pharmacopoeia monograph reference 

Not applicable
Indication(s) 

Traditional herbal medicinal product to relieve symptoms of discomfort and heaviness of legs related to minor venous circulatory disturbances.

The product is a traditional herbal medicinal product for use in specified indication exclusively based upon long-standing use.
Type of tradition 

European
Specified strength 

Please see “Specified posology”.
Specified posology 
Adults and elderly 

Soft extract (2.5-4:1; extraction solvent water) in a cream base (10 g contain 282 mg soft extract).

Apply a thin layer on the affected area 1-3 times daily.

The use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precautions for use”).
Route of administration 

Cutaneous use.
Duration of use or any restrictions on the duration of use 
Adults and elderly 

The recommended duration of use is 4 weeks.

If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
Any other information necessary for the safe use 
Contraindications 

Hypersensitivity to the active substance.
Special warnings and precautions for use 

If there is inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency, a doctor should be consulted.

The product should not be used on broken skin, around the eyes or on mucous membranes.

In the absence of sufficient safety data, the use in children and adolescents below 18 years of age is not recommended.
Interactions with other medicinal products and other forms of interaction 

None reported.
Pregnancy and lactation 

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Effects on ability to drive and use machines 

No studies on the effect on the ability to drive and use machines have been performed.
Undesirable effects 

Contact allergy and/or hypersensitivity reactions of the skin (itching and erythema, urticaria) have been reported. The frequency is not known.

If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
Overdose 

No case of overdose has been reported.
Pharmaceutical particulars (if necessary) 

Not applicable.
Pharmacological effects or efficacy plausible on the basis of long-standing use and experience (if necessary for the safe use of the product) 

Not applicable.
'
